Sun Pharma Advanced Research Co. Ltd.’s (SPARC) baclofen GRS for the treatment of spasticity in patients with multiple sclerosis has failed to meet its primary endpoint in placebo controlled studies in the US, casting a shadow on the firm’s short-term outlook. SPARC is the listed spin-off R&D arm of India’s top-ranked pharma company, Sun Pharmaceutical Industries Ltd..
Baclofen Setback Forces Sun R&D Arm Towards Difficult Choices
Sun Pharma Advanced Research Company’s baclofen GRS has failed to meet its primary endpoint in a US Phase III study, posing several tough questions for the firm. It may have to advance partnering plans for some assets and also review its cash flow situation closely.
